Literature DB >> 15363539

Genetic progression of metastatic melanoma.

Monica Rodolfo1, Maria Daniotti, Viviana Vallacchi.   

Abstract

Melanoma progression is well defined in its clinical, histopathological and biological aspects, but the molecular mechanism involved and the genetic markers associated to metastatic dissemination are only beginning to be defined. The recent development of high-throughput technologies aimed at global molecular profiling of cancer is switching on the spotlight at previously unknown candidate genes involved in melanoma, such as WNT5A and BRAF. In fact, several tumor suppressors and oncogenes have been shown to be involved in melanoma pathogenesis, including CDKN2A, PTEN, TP53, RAS and MYC, though they have not been related to melanoma subtypes or validated as prognostic markers. Here, we have reviewed the published data relative to the major genes involved in melanoma pathogenesis, which may represent important markers for the identification of genetic profiles of melanoma subtypes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15363539     DOI: 10.1016/j.canlet.2004.06.049

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  11 in total

1.  DNAJB6 chaperones PP2A mediated dephosphorylation of GSK3β to downregulate β-catenin transcription target, osteopontin.

Authors:  A Mitra; M E Menezes; L K Pannell; M S Mulekar; R E Honkanen; L A Shevde; R S Samant
Journal:  Oncogene       Date:  2012-01-23       Impact factor: 9.867

Review 2.  Gene signature of the metastatic potential of cutaneous melanoma: too much for too little?

Authors:  József Tímár; Balázs Gyorffy; Erzsébet Rásó
Journal:  Clin Exp Metastasis       Date:  2010-02-24       Impact factor: 5.150

3.  Use of human tissue to assess the oncogenic activity of melanoma-associated mutations.

Authors:  Yakov Chudnovsky; Amy E Adams; Paul B Robbins; Qun Lin; Paul A Khavari
Journal:  Nat Genet       Date:  2005-06-12       Impact factor: 38.330

Review 4.  Melanoma genetics and the development of rational therapeutics.

Authors:  Yakov Chudnovsky; Paul A Khavari; Amy E Adams
Journal:  J Clin Invest       Date:  2005-04       Impact factor: 14.808

5.  CTLA-4 is a direct target of Wnt/beta-catenin signaling and is expressed in human melanoma tumors.

Authors:  Kavita V Shah; Andy J Chien; Cassian Yee; Randall T Moon
Journal:  J Invest Dermatol       Date:  2008-06-19       Impact factor: 8.551

6.  Assaying Wnt5A-mediated invasion in melanoma cells.

Authors:  Michael P O'Connell; Amanda D French; Poloko D Leotlela; Ashani T Weeraratna
Journal:  Methods Mol Biol       Date:  2008

7.  EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy.

Authors:  Nikola Holtkamp; Elke Malzer; Jan Zietsch; Ali Fuat Okuducu; Jana Mucha; Christian Mawrin; Victor-F Mautner; Hans-Ulrich Schildhaus; Andreas von Deimling
Journal:  Neuro Oncol       Date:  2008-07-23       Impact factor: 12.300

Review 8.  Uveal vs. cutaneous melanoma. Origins and causes of the differences.

Authors:  Carolina Belmar-Lopez; Pablo Mancheno-Corvo; Maria Antonia Saornil; Patrick Baril; Georges Vassaux; Miguel Quintanilla; Pilar Martin-Duque
Journal:  Clin Transl Oncol       Date:  2008-03       Impact factor: 3.405

9.  Deletion at chromosome arm 9p in relation to BRAF/NRAS mutations and prognostic significance for primary melanoma.

Authors:  Caroline Conway; Samantha Beswick; Faye Elliott; Yu-Mei Chang; Juliette Randerson-Moor; Mark Harland; Paul Affleck; Jerry Marsden; D Scott Sanders; Andy Boon; Margaret A Knowles; D Timothy Bishop; Julia A Newton-Bishop
Journal:  Genes Chromosomes Cancer       Date:  2010-05       Impact factor: 5.006

10.  BRAFV600E mutations in malignant melanoma are associated with increased expressions of BAALC.

Authors:  David Schrama; Gunhild Keller; Roland Houben; Christian G Ziegler; Claudia S Vetter-Kauczok; Selma Ugurel; Jürgen C Becker
Journal:  J Carcinog       Date:  2008-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.